Protalix Biotherapeutics Price To Earning vs. Revenue

PLX Stock  USD 1.68  0.03  1.75%   
Based on Protalix Biotherapeutics' profitability indicators, Protalix Biotherapeutics is yielding more profit at this time then in previous quarter. It has a moderate odds of reporting better profitability numbers in December. Profitability indicators assess Protalix Biotherapeutics' ability to earn profits and add value for shareholders. Price To Sales Ratio is likely to drop to 1.74 in 2024. Days Sales Outstanding is likely to drop to 27.91 in 2024. At this time, Protalix Biotherapeutics' Operating Income is fairly stable compared to the past year. Income Before Tax is likely to rise to about 9 M in 2024, despite the fact that Total Other Income Expense Net is likely to grow to (1.8 M).
Current ValueLast YearChange From Last Year 10 Year Trend
Gross Profit Margin0.680.6491
Sufficiently Up
Slightly volatile
For Protalix Biotherapeutics profitability analysis, we use financial ratios and fundamental drivers that measure the ability of Protalix Biotherapeutics to generate income relative to revenue, assets, operating costs, and current equity. These fundamental indicators attest to how well Protalix Biotherapeutics utilizes its assets to generate profit and value for its shareholders. The profitability module also shows relationships between Protalix Biotherapeutics's most relevant fundamental drivers. It provides multiple suggestions of what could affect the performance of Protalix Biotherapeutics over time as well as its relative position and ranking within its peers.
  
Check out Your Equity Center.
For more information on how to buy Protalix Stock please use our How to Invest in Protalix Biotherapeutics guide.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Protalix Biotherapeutics. If investors know Protalix will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Protalix Biotherapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth
(0.39)
Earnings Share
(0.15)
Revenue Per Share
0.522
Quarterly Revenue Growth
(0.62)
Return On Assets
(0.10)
The market value of Protalix Biotherapeutics is measured differently than its book value, which is the value of Protalix that is recorded on the company's balance sheet. Investors also form their own opinion of Protalix Biotherapeutics' value that differs from its market value or its book value, called intrinsic value, which is Protalix Biotherapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Protalix Biotherapeutics' market value can be influenced by many factors that don't directly affect Protalix Biotherapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Protalix Biotherapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Protalix Biotherapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Protalix Biotherapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

Protalix Biotherapeutics Revenue vs. Price To Earning Fundamental Analysis

Comparative valuation techniques use various fundamental indicators to help in determining Protalix Biotherapeutics's current stock value. Our valuation model uses many indicators to compare Protalix Biotherapeutics value to that of its competitors to determine the firm's financial worth.
Protalix Biotherapeutics is regarded fifth in price to earning category among its peers. It is regarded fourth in revenue category among its peers . At this time, Protalix Biotherapeutics' Total Revenue is fairly stable compared to the past year. The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Protalix Biotherapeutics' earnings, one of the primary drivers of an investment's value.

Protalix Revenue vs. Price To Earning

Price to Earnings ratio is typically used for current valuation of a company and is one of the most popular ratios that investors monitor daily. Holding a low PE stock is less risky because when a company's profitability falls, it is likely that earnings will also go down as well. In other words, if you start from a lower position, your downside risk is limited. There are also some investors who believe that low Price to Earnings ratio reflects the low pricing because a given company is in trouble. On the other hand, a higher PE ratio means that investors are paying more for each unit of profit.

Protalix Biotherapeutics

P/E

 = 

Market Value Per Share

Earnings Per Share

 = 
(1.23) X
Generally speaking, the Price to Earnings ratio gives investors an idea of what the market is willing to pay for the company's current earnings.
Revenue is income that a firm generates from business activities such us rendering services or selling goods to customers. It is a crucial part of a business and an essential item when evaluating a company's financial statements. Revenues from a firm's primary business operations can be reported on the income statement as sales revenue, net sales, or simply sales, depending on the industry in which a given company operates.

Protalix Biotherapeutics

Revenue

 = 

Money Received

-

Discounts and Returns

 = 
65.49 M
Revenue is typically recorded when cash or cash equivalents are exchanged for services or goods and can include products or services discounts, promotions, as well as early payments on invoices or services rendered in advance.

Protalix Revenue vs Competition

Protalix Biotherapeutics is regarded fourth in revenue category among its peers. Market size based on revenue of Health Care industry is at this time estimated at about 742.59 Million. Protalix Biotherapeutics holds roughly 65.49 Million in revenue claiming about 9% of equities under Health Care industry.

Protalix Biotherapeutics Profitability Projections

The most important aspect of a successful company is its ability to generate a profit. For investors in Protalix Biotherapeutics, profitability is also one of the essential criteria for including it into their portfolios because, without profit, Protalix Biotherapeutics will eventually generate negative long term returns. The profitability progress is the general direction of Protalix Biotherapeutics' change in net profit over the period of time. It can combine multiple indicators of Protalix Biotherapeutics, where stable trends show no significant progress. An accelerating trend is seen as positive, while a decreasing one is unfavorable. A rising trend means that profits are rising, and operational efficiency may be rising as well. A decreasing trend is a sign of poor performance and may indicate upcoming losses.
Last ReportedProjected for Next Year
Operating Income10.5 M11 M
Income Before Tax8.6 MM
Total Other Income Expense Net-1.9 M-1.8 M
Net Income8.3 M8.7 M
Income Tax Expense254 K241.3 K
Net Income From Continuing Ops8.3 M8.7 M
Non Operating Income Net Other-6.8 M-7.1 M
Net Loss-13.4 M-14.1 M
Net Interest Income-1.9 M-2 M
Interest Income1.3 M686.3 K
Change To Netincome639.4 K607.4 K
Net Income Per Share 0.12  0.13 
Income Quality(0.16)(0.15)
Net Income Per E B T 0.97  1.02 

Protalix Profitability Driver Comparison

Profitability drivers are factors that can directly affect your investment outlook on Protalix Biotherapeutics. Investors often realize that things won't turn out the way they predict. There are maybe way too many unforeseen events and contingencies during the holding period of Protalix Biotherapeutics position where the market behavior may be hard to predict, tax policy changes, gold or oil price hikes, calamities change, and many others. The question is, are you prepared for these unexpected events? Although some of these situations are obviously beyond your control, you can still follow the important profit indicators to know where you should focus on when things like this occur. Below are some of the Protalix Biotherapeutics' important profitability drivers and their relationship over time.

Use Protalix Biotherapeutics in pair-trading

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Protalix Biotherapeutics position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Protalix Biotherapeutics will appreciate offsetting losses from the drop in the long position's value.

Protalix Biotherapeutics Pair Trading

Protalix Biotherapeutics Pair Trading Analysis

The ability to find closely correlated positions to Protalix Biotherapeutics could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Protalix Biotherapeutics when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Protalix Biotherapeutics - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Protalix Biotherapeutics to buy it.
The correlation of Protalix Biotherapeutics is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Protalix Biotherapeutics moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Protalix Biotherapeutics moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Protalix Biotherapeutics can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.
Pair CorrelationCorrelation Matching

Use Investing Themes to Complement your Protalix Biotherapeutics position

In addition to having Protalix Biotherapeutics in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.

Did You Try This Idea?

Run Sector ETFs Thematic Idea Now

Sector ETFs
Sector ETFs Theme
ETF themes focus on helping investors to gain exposure to a broad range of assets, diversify, and lower overall costs. The Sector ETFs theme has 439 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Sector ETFs Theme or any other thematic opportunities.
View All  Next Launch

Additional Tools for Protalix Stock Analysis

When running Protalix Biotherapeutics' price analysis, check to measure Protalix Biotherapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Protalix Biotherapeutics is operating at the current time. Most of Protalix Biotherapeutics' value examination focuses on studying past and present price action to predict the probability of Protalix Biotherapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Protalix Biotherapeutics' price. Additionally, you may evaluate how the addition of Protalix Biotherapeutics to your portfolios can decrease your overall portfolio volatility.